US8481573 — Modulators of sphingosine phosphate receptors
Method of Use · Assigned to Scripps Research Institute · Expires 2033-03-24 · 7y remaining
What this patent protects
This patent protects compounds that activate a specific receptor and are useful in treating conditions such as multiple sclerosis, transplant rejection, and adult respiratory syndrome.
USPTO Abstract
Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2774 |
— | ozanimod-hydrochloride |
U-2774 |
— | ozanimod-hydrochloride |
U-2774 |
— | ozanimod-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.